Asa Christina Laurell

Asa Christina Laurell

Auto-generated profile, based on publicly available information

Asa Christina Laurell

Instituto Mexicano del Seguro Social, Dirección de Planeación para la Transformación Institucional. Ciudad de México, México

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025
Verified
Journal Article
Open access
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
RRRodolfo Rivas-Ruiz
Rodolfo Rivas-Ruiz
IRIvonne Analí Roy-García
Ivonne Analí Roy-García
EFEduardo Antonio Ferat-Osorio
Eduardo Antonio Ferat-Osorio
OCOCTAVIO CASTRO-ESCAMILLA
OCTAVIO CASTRO-ESCAMILLA
ALAsa Christina Laurell
Asa Christina Laurell
One of the main goals in the treatment of patients with type 2 diabetes (T2D) is the prevention of its complications. Most existing studies have evaluated a limited and isolated number of inflammatory molecules and metabolic factors, and only rarely have clinical and lifestyle variables been jointly considered. The objective of this study is to describe the protocol design for a comprehensive assessment of patients with T2D, considering glycemic control and the development of complications. A cross-sectional, observational, and multicenter study was conducted in three primary care units located in the states of Coahuila, Jalisco, and Veracruz. Glycemic dysregulation will be assessed by measuring glycated hemoglobin, while diabetic nephropathy will be identified through alterations in the glomerular filtration rate. Additionally, clinical and biochemical parameters, lifestyle habits, physical condition, type of treatment, treatment adherence, and nutritional aspects will be evaluated. Furthermore, transcriptomic analysis using RNA-Seq will be performed to identify the genes that best stratify and distinguish patients with glycemic dysregulation, metabolic alterations, and diabetic nephropathy through principal component analysis and ROC curves based on relative RNA expression. To determine clinical factors associated with the link between molecular profiles and glycemic dysregulation, multiple logistic regression models will be developed to identify a pathological molecular signature characteristic of the disease.